Created
July 23, 2019 17:52
-
-
Save xanderdunn/7c4409c23d724a3f768fc5592f2c32b8 to your computer and use it in GitHub Desktop.
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Company | Founded | Product | Type | Furthest Research | Started | Fate | Outcome | Notes | |
---|---|---|---|---|---|---|---|---|---|
Wyeth Pharmaceuticals (Pfizer) | stamulumab (MYO-029) | antibody | Phase 2 Clinical Muscular Dystrophy | 2005 | dead | didn't achieve significant muscle gain | |||
Novartis & MorphoSys | 1992 | bimagrumab (BYM-338) | antibody | Phase 2b/3 Sporadic Inclusion Body Myositis | 2013 | dead | didn't achieve significant muscle gain | ||
Phase 2 Hip Fracture | 2014 | ongoing | |||||||
Phase 2 Sarcopenia | 2012 | completed | |||||||
Phase 2 Chronic Obstructive Pulmonary Disease | 2012 | completed | |||||||
Phase 2 Cachexia | 2011 | completed | |||||||
Phase 2 Diabetes | 2016 | ongoing | |||||||
Scholar Rock | 2012 | SRK-015 | antibody | Expected to file IND Q2 2018 for spinal muscular atrophy | ongoing | ||||
Atara (Amgen) | 2012 | PINTA-745 | peptibody | Phase 2 End Stage Renal Disease | 2013 | dead | didn't achieve significant muscle gain | ||
Acceleron & Shire | 2004/1986 | ACE-031 | antibody | Phase 2 Muscular Dystrophy | 2010 | dead | toxicity | ||
ACE-083 | protein | FSHD | 2016 | ongoing | |||||
Phase 2 Charcot-Marie-Tooth Disease | 2017 | ongoing | |||||||
ACE-2494 | protein | Phase 1 Healthy Volunteers | 2018 | ongoing | |||||
Milo Biotechnology | 2011 | rAAV1.CMV.huFollistin344 | gene | Phase 1/2 Muscular Dystrophy | 2012 | ongoing | |||
Pfizer | 1849 | domagrozumab (PF-06252616) | anitbody | Phase 2 Muscular Dystrophy | 2016 | dead | didn't achieve significant muscle gain | ||
Phase 1b/2 LGMD2I | 2016 | dead | |||||||
Eli Lilly | 1876 | landogrozumab (LY2495655) | antibody | Phase 2 Advanced Cancer | 2012 | completed | |||
Phase 2 Muscle Weakness | 2012 | completed | |||||||
Phase 2 Muscle Atrophy | 2011 | dead | didn't achieve significant muscle gain | ||||||
Bristol-Myers Squibb & Roche | 1887/1896 | BMS-986089 | protein | Phase 2/3 Duchenne Muscular Dystrophy | 2017 | ongoing | |||
Immusoft | 2009 | cell | Expect to file IND Q4 2019 | ongoing | |||||
AliveGen | 2014 | unknown | Phase I | unknown | unknown | ||||
Paranta Bio | 2009 | PB01 | protein (recombinant FST 288) | Sam Coleman mentioned | |||||
Ossianix | 2011 | antibody | Sam Coleman mentioned | ||||||
Regeneron | 1988 | GARETOSMAB | antibody (activin A) | Phase 2 Fibrodysplasia Ossificans Progressiva | |||||
TREVOGRUMAB | antibody (GDF8) | Phase 1 Muscle-wasting diseases | |||||||
Genentech & Roche | 1976/1896 | RG6206 | |||||||
AAVogen | 2015 |
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment